Physician profile
Christopher D Miller
NPI 1356349880
$979.19
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $213.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $154.57 | 2019-2020 | |
| Novo Nordisk INC | $134.43 | 2019 | |
| Merck Sharp & Dohme LLC | $95.73 | 2019 | |
| Abbott Laboratories | $85.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.62 | 2019-2020 | |
| Dexcom, INC. | $77.13 | 2019-2020 | |
| Lilly USA, LLC | $51.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $43.04 | 2019-2020 | |
| Ibsa Pharma INC. | $35.90 | 2019 | |
| Amgen INC. | $30.76 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.00 | 2020 | |
| Shire North American Group INC | $22.56 | 2019 | |
| Amarin Pharma, INC. | $21.21 | 2019 | |
| Companion Medical, INC. | $20.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.29 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.01 | 2020 | |
| Horizon Therapeutics Plc | $19.13 | 2019 | |
| Insulet Corporation | $15.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.63 | 2019 | |
| Medtronic Minimed, INC. | $13.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.